Article

Alcon's Cary Rayment honored as a 'catalyst' for glaucoma work

Cary Rayment, who was honored Jan. 23 by the Glaucoma Research Foundation (GRF) with the 2008 GRF Catalyst Award, is leading his company's strategic plan to spend more than $3.5 billion on research over the next 5 years.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200
March 20th 2025

Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Stem cell-based CALEC therapy achieves 90% corneal surface restoration in clinical trial
March 20th 2025

Stem cell-based CALEC therapy achieves 90% corneal surface restoration in clinical trial

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

OSRX expands medication sizes and adds direct-to-patient post-op kits
March 19th 2025

OSRX expands medication sizes and adds direct-to-patient post-op kits

Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes
March 19th 2025

Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes

© 2025 MJH Life Sciences

All rights reserved.